Recce Pharmaceuticals Announces Positive Data on RECCE 327 Against Neisseria gonorrhoeae in STD Animal Model - Seite 2

*(P<0.05) significantly different from vehicle control;
** PI – Post Infection
*** Treatment began two days post infection and received IV bolus twice daily duration of treatment - seven days

The study director concluded, “RECCE 327 showed significant dose dependent antibacterial effect in vaginal load at 100, 500 and 1000 mg/kg given by intravenous (IV) bolus when compared to the control group seven days post infection."

In this study Meropenem, a broad spectrum carbapenem antibiotic, was used at its optimum dose as the recognized efficacy model. In practice however, Meropenem’s high rates of bacterial resistance have recently led to restriction of its use, now reserved for infections caused by resistant organisms.²

The World Health Organization (WHO) lists N. gonorrhoeae as a priority pathogen on its list of antibiotic-resistant bacteria that pose the greatest threat to human health.³ The leading national public health institute of the U.S., the Centers for Disease Control and Prevention (CDC) estimates drug-resistant N. gonorrhoeae results in 550,000 infections each year, with a total of 1.14 million infections from N. gonorrhoeae annually.⁴

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialization of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs.

Recce antibiotics are unique – their potency does not diminish even with repeated use, which is a common failure associated with existing antibiotic use and the resulting emergence of resistant superbugs.

Patented lead candidate RECCE 327, wholly owned and manufactured in Australia, has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms.

The FDA has awarded RECCE 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Executive Director	Media & Investor Relations (AU)	Media & Investor Relations (USA)
James Graham	Andrew Geddes	Meredith Sosulski, PhD
Reece Pharmaceuticals, Ltd.	CityPR	LifeSci Communications
[phone]	[phone]	[phone]
[e-mail]	[e-mail]	[e-mail]

¹ NCBI, National Institute of Health